LEADER 03989oam 2200673I 450 001 9910557424603321 005 20190503073416.0 010 $a0-262-31460-6 035 $a(CKB)2550000001163178 035 $a(EBL)3339710 035 $a(SSID)ssj0001062521 035 $a(PQKBManifestationID)11675612 035 $a(PQKBTitleCode)TC0001062521 035 $a(PQKBWorkID)11017329 035 $a(PQKB)10937775 035 $a(StDuBDS)EDZ0000234245 035 $a(MiAaPQ)EBC3339710 035 $a(OCoLC)863672798$z(OCoLC)868916158$z(OCoLC)881734135$z(OCoLC)990660707 035 $a(OCoLC-P)863672798 035 $a(MaCbMITP)9876 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/78519 035 $a(EXLCZ)992550000001163178 100 $a20131122d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aSchizophrenia $eevolution and synthesis /$fedited by Steven M. Silverstein, Bita Moghaddam, and Til Wykes ; program advisory committee, Anil K. Malhotra, John McGrath, Andreas Meyer-Lindenberg, Bita Moghaddam, Steven M. Silverstein, Til Wykes 210 1$aCambridge, Massachusetts ;$aLondon, England :$cThe MIT Press,$d[2013] 210 4$dİ2013 215 $a1 online resource (403 p.) 225 1 $aStru?ngmann Forum reports 300 $aDescription based upon print version of record. 311 $a0-262-01962-0 311 $a1-306-14065-X 320 $aIncludes bibliographies and index. 327 $aContents; The Ernst Stru?ngmann Forum; List of Contributors; 1 Schizophrenia; Heterogeneity; 2 What Kind of a Thing Is Schizophrenia?; 3 How the Diagnosis of Schizophrenia Impeded the Advance of Knowledge (and What to Do About It); 4 What Dimensions of Heterogeneity Are Relevant for Treatment Outcome?; 5 Which Aspects of Heterogeneity Are Useful to Translational Success?; Risk and Resilience; 6 How Should Resilience Factors Be Incorporated in Treatment Development?; 7 Insights into New Treatments for Early Psychosis from Genetic, Neurodevelopment,and Cognitive Neuroscience Research 327 $a8 From Epidemiology to Mechanisms of Illness9 How Can Risk and Resilience Factors Be Leveraged to Optimize Discovery Pathways?; Models; 10 Human Cell Models for Schizophrenia; 11 How Can Animal Models Be Better Utilized?; 12 How Can Computational Models Be Better Utilized for Understanding and Treating Schizophrenia?; 13 How Can Models Be Better Utilized to Enhance Outcome?; Development and Treatment; 14 Why Kraepelin Was Right; 15 What Will the Next Generation of Psychosocial Treatments Look Like?; 16 Creative Solutions to Overcoming Barriers in Treatment Utilization 327 $a17 What Is Necessary to Enhance Development and Utilization of Treatment?Bibliography; Subject Index 330 8 $aDespite major advances in methodology and thousands of published studies every year, treatment outcomes in schizophrenia have not improved over the last 50 years. Moreover, we still lack strategies for prevention and we do not yet understand how the interaction of genetic, developmental, and environmental factors contribute to the disorder. In this book, leading researchers consider conceptual and technical obstacles to progress in understanding schizophrenia and suggest novel strategies for advancing research and treatment. 410 0$aStru?ngmann Forum Reports 606 $aSchizophrenia 606 $aSchizophrenia$xEtiology 606 $aClinical medicine$xDecision making 610 $aNEUROSCIENCE/General 615 0$aSchizophrenia. 615 0$aSchizophrenia$xEtiology. 615 0$aClinical medicine$xDecision making. 676 $a616.89/8 702 $aSilverstein$b Steven M. 702 $aMoghaddam$b Bita 702 $aWykes$b Til 801 0$bOCoLC-P 801 1$bOCoLC-P 906 $aBOOK 912 $a9910557424603321 996 $aSchizophrenia$91411695 997 $aUNINA